CYB004
Generalized Anxiety Disorder (GAD)
Phase 2Enrollment Completed
Key Facts
Indication
Generalized Anxiety Disorder (GAD)
Phase
Phase 2
Status
Enrollment Completed
Company
About Helus Pharma
Helus Pharma's mission is to provide treatments designed to foster durable improvements in mental health by strategically innovating novel serotonergic agonists (NSAs). The company has achieved significant milestones, including completing enrollment in a Phase 2 study for CYB004 in Generalized Anxiety Disorder (GAD) and reporting topline results from a Phase 2 signal detection study for HLP004 in the same indication. Its strategy centers on leveraging a proprietary technology platform that pairs NSAs with deuteration to create consistent, patent-protected, and scalable therapies, backed by a leadership team with extensive drug development and commercialization expertise.
View full company profileTherapeutic Areas
Other Generalized Anxiety Disorder (GAD) Drugs
| Drug | Company | Phase |
|---|---|---|
| Generalized Anxiety Disorder Treatment | Viatris (2) | Approved (Japan) |
| NTX-1955 | Newleos | Phase 1b |
| Luvesilocin (RE104) | Reunion Neuroscience | Pre-clinical/Planned |
| DT120 | Definium Therapeutics | Phase 3 |
| HLP004 | Helus Pharma | Phase 2 |
| Psi-GAD | Incannex Healthcare | Phase 2 |
| BNC210 | Neuphoria Therapeutics | Phase 2 |